Latest news with #VeronaPharma
Yahoo
a day ago
- Business
- Yahoo
Jim Cramer Notes Verona Pharma plc (VRNA) 'Loses a Lot of Money'
We recently published a list of . In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other stocks that Jim Cramer discusses. Answering a caller's query about Verona Pharma plc (NASDAQ:VRNA), Cramer stated: 'That stock is a rocket ship. Again, very very speculative, because it loses a lot of money. Does have a couple things in the pipe that people like, but also has a huge amount of insider selling, frankly.' A patient in a clinic, taking a medication dose from a nebulizer to treat a respiratory disease. Verona Pharma (NASDAQ:VRNA) is a biopharmaceutical company developing treatments for respiratory diseases with limited treatment options. The company's lead therapy, Ohtuvayre, is designed to provide bronchodilation and anti-inflammatory benefits for conditions like COPD, cystic fibrosis, and asthma. Buckley Capital Advisors stated the following regarding Verona Pharma plc (NASDAQ:VRNA) in its Q1 2025 investor letter: 'Verona Pharma plc (NASDAQ:VRNA) has developed a product called ensifentrine (Ohtuvayre), a bronchodilator and anti-inflammatory agent for maintenance treatment of COPD. COPD, more commonly known as smoker's lung, is caused by pollution or smoking. Diagnosis of COPD lowers life expectancy by approximately 6 years. Symptoms of COPD are shortness of breath, cough, wheezing, and sputum. COPD affects approximately 400 million people worldwide, with 8.6m people treated in the United States. Overall, VRNA ranks 7th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of VRNA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VRNA and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
CNBC
5 days ago
- Business
- CNBC
Lightning Round: Valero has had too much of a run, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Valero, IONQ, Verona Pharma, Centrus Energy, and Oklo.
Yahoo
21-05-2025
- Business
- Yahoo
Verona Pharma Announces June 2025 Investor Conference Participation
LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ('Verona Pharma' or the 'Company') announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 11:05 a.m. ET / 4:05 p.m. BSTLocation: New York, NY Goldman Sachs 46th Annual Global Healthcare ConferenceDate: Monday, June 9, 2025Time: 2:40 p.m. ET / 7:40 p.m. BSTLocation: Miami, FL A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company's website, For further information please contact: Verona Pharma plc Tel: +1-844-341-9901 Victoria Stewart, Senior Director of Investor Relations and Communications IR@ Argot PartnersUS Investor Enquiries Tel: +1-212-600-1902verona@ Ten Bridge CommunicationsInternational / US Media Enquiries Tel: +1-781-316-4424tbcverona@ Wendy Ryan About Verona Pharma Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre® (ensifentrine) is the Company's first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
Verona Pharma Announces June 2025 Investor Conference Participation
LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ('Verona Pharma' or the 'Company') announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 11:05 a.m. ET / 4:05 p.m. BSTLocation: New York, NY Goldman Sachs 46th Annual Global Healthcare ConferenceDate: Monday, June 9, 2025Time: 2:40 p.m. ET / 7:40 p.m. BSTLocation: Miami, FL A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company's website, For further information please contact: Verona Pharma plc Tel: +1-844-341-9901 Victoria Stewart, Senior Director of Investor Relations and Communications IR@ Argot PartnersUS Investor Enquiries Tel: +1-212-600-1902verona@ Ten Bridge CommunicationsInternational / US Media Enquiries Tel: +1-781-316-4424tbcverona@ Wendy Ryan About Verona Pharma Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre® (ensifentrine) is the Company's first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Nuance seeks China approval for Ohtuvayre following Phase III trial success
Nuance Pharma's Ohtuvayre (ensifentrine) has met the primary endpoint in a Phase III chronic obstructive pulmonary disease (COPD) study in China. The medication was developed as part of a partnership with UK company Verona Pharma. In the ENHANCE-CHINA trial (NCT05743075), nebulised Ohtuvayre showed a statistically significant and clinically meaningful improvement in change in forced expiratory volume (FEV) of 110ml after 12 weeks. The trial also showed improvement in lung function, including a peak FEV of 174mL, a morning trough FEV increase of 36ml and an evening trough FEV increase of 65ml. Patients also receiving saw a 28% reduction in the rate of moderate/severe COPD exacerbations over 24 weeks, and there was a decrease in the risk of a moderate/severe exacerbation, measured by time to first exacerbation of 25%. There was also improvement in secondary endpoints, including dyspnea as measured by the Transition Dyspnea Index (TDI) of 0.8 compared to placebo over 24 weeks. Quality of Life (QoL), as measured by the St George's Respiratory Questionnaire (SGRQ) Total Score in the Ohtuvayre arm, also improved by -2.9, higher than the Minimal Clinically Important Difference (MCID) of -4. The therapy remained well-tolerated with adverse event (AE) incidence similar to placebo. Nuance Pharma CEO Mark Lotter said: "These promising results demonstrate Ohtuvayre's strength as a first-in-class bronchodilator and non-steroidal anti-inflammatory therapy for COPD, as an advance to existing treatment options.' Nuance Pharma plans to submit a new drug application to China's National Medical Products Administration (NMPA) in the second half of 2025. Shanghai-based Nuance gained rights to Ohtuvayre in June 2021 after signing a $219m strategic collaboration with Verona Pharma. The collaboration gave Nuance Pharma development and commercial rights in Greater China. Ohtuvayre is a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4) that combines bronchodilator and non-steroidal anti-inflammatory effects delivered through a standard jet nebuliser. The drug was approved by the US Food and Drug Administration (FDA) on 26 June 2024 for use in adult COPD patients. Approval for use in Europe has yet to be granted. Nuance Pharma plans to release additional information from ENHANCE-CHINA at upcoming scientific conferences. According to GlobalData, Ohtuvayre could reach global sales of $1.63bn in 2030. GlobalData is the parent company of Clinical Trials Arena. "Nuance seeks China approval for Ohtuvayre following Phase III trial success" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
